united states food drug administration modernization act fdama amended federal food drug cosmetic act act related regulation food drugs devices biological products fda changes made order recognize changes way fda would operating century main focus acknowledgment advancement technological trade public health complexities congressman richard burr senator james jeffords chairperson sponsors food drug administration regulatory modernization act food drug administration modernization act us legislation signed bill clinton november fully enacted april putting law reforms begun national partnership reinventing government one result passing act reduction time approval new pharmaceutical fda modernization act piece legislation concentrated reforming regulation food medical products cosmetics united states following significant provisions act act reauthorized five years prescription drug user fee act pdufa purpose enable fda reduce average time required drug review months months law enacts many fda initiatives undertaken recent years vice president al gores reinventing government program codified initiatives include measures modernize regulation biological products bringing harmony regulations drugs eliminating need establishment license application eliminate batch certification monograph requirements insulin antibiotics streamline approval processes drug biological manufacturing changes reduce need environmental assessment part product application act also codifies fda regulations practice increase patient access experimental drugs medical devices accelerate review important new medications addition law provides expanded database clinical trials accessible patients sponsors consent results clinical trials included database separate provision patients receive advance notice manufacturer plans discontinue drug depend life support sustenance treatment serious debilitating disease condition law abolishes longstanding prohibition broadcasting manufacturers information unapproved uses drugs medical devices act allows firm circulate peerreviewed journal articles offlabel indication product providing company also committing file proof research within certain amount time act also allows drug companies provide economic information products formulary committees managed care organizations similar largescale buyers healthcare products provision intended provide entities dependable facts economic consequences procurement decisions law however permit spreading economic information could affect prescribing choices individual medical practitioners act creates special exemption ensure continued availability compounded drug products prepared pharmacists provide patients individualized therapies available commercially law however seeks prevent manufacturing guise compounding establishing parameters within practice appropriate lawful act complements builds fdas recent measures focus resources medical devices present greatest risks patients example law exempts premarket notification class devices intended use substantial importance preventing impairment human health present potential unreasonable risk illness injury law also directs fda focus post market surveillance higher risk devices allows agency implement reporting system concentrates representative sample user hospitals nursing experience deaths serious illnesses injuries linked use devices finally law expands ongoing pilot program fda accredits third conduct initial review lowtointermediate risk class ii devices act however specifies accredited person may review devices permanently implantable lifesupporting life sustaining clinical data required act eliminates requirement fdas premarket approval packaging substances come contact food may migrate instead law establishes process whereby manufacturer notify agency intent use certain food contact substances unless fda objects within days manufacturer may proceed marketing new product implementation notification process contingent additional appropriations cover cost agency act also expands procedures fda authorize health claims nutrient content claims without reducing statutory standard act reduces simplifies many regulatory obligations manufacturers lower standards medical products introduced market place area drugs law codifies agencys current practice allowing certain circumstances one clinical investigation basis product approval act however preserve presumption general rule two adequate wellcontrolled studies needed prove products safety effectiveness area medical devices act specifies fda may keep market products whose manufacturing processes deficient could present serious health hazard law also gives agency authority take appropriate action technology device suggests likely used potentially harmful unlabeled fdama required specifications addition many provisions required completed specific time period specified fdama implementation chart completed items exploration began act government established clinicaltrialsgov result biggest complaint regards act amount time money effort would require act required government make good lot promises within fda october acting commissioner food drug administration michael friedman md said regards acts implementation coming time vigorous scientific growth implementing fdama one demanding challenges faced agency year history challenge albeit one believe substantially met promulgate many regulations guidances take steps necessary effectuate changes set forth statute thoroughly committed meeting challenge critics questioned necessity act stating federal food drug cosmetic act substantial legislature addition many questioned whether shortened time frame approval prescription drugs would harm